SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    Form 8-K



                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934



        Date of Report (Date of earliest event reported) October 10, 2002



                           Dragon Pharmaceutical, Inc.
             (Exact name of registrant as specified in its charter)


            Florida                      0-27937                 65-0142474
            -------                      -------                 ----------
  (State or other jurisdiction of      (Commission            (I.R.S. Employer
  incorporation or organization)       File Number)          Identification No.)




                      1055 West Hastings Street, Suite 1900
                           Vancouver, British Columbia
                                 Canada V6E 2E9
                    (Address of principal executive offices)

                                 (604) 669-8817
                           (Issuer's telephone number)




<PAGE>


Item 5.  Other Events and Regulation FD Disclosure

On October 10, 2002,  Dragon  Pharmaceutical  announced  that Alexander Wick had
been named as President and Chief Executive Officer.

A copy of the  press  release  announcing  the  naming of Mr.  Wick is  included
herewith as an exhibit to this report.

Item 7.  Financial Statements and Exhibits.

         (c)      Exhibits.

                  99.1     Press release dated October 10, 2002.


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: October 10, 2002                     Dragon Pharmaceutical, Inc.
                                            a Florida Corporation


                                            /S/ Matthew Kavanagh
                                            ----------------------------
                                            Matthew Kavanagh,
                                            Principal Accounting Officer


<PAGE>



Exhibit 99.1 Press Release

DRAGON APPOINTS NEW PRESIDENT

Vancouver,   BC  -  October  10,  2002  -  The  Board  of  Directors  of  Dragon
Pharmaceuticals Inc. (TSX: DDD; OTC BB: DRUG) today announced the appointment of
Dr.  Alexander  E.  Wick as  President.  Dr.  Wick will  continue  to serve as a
Director of Dragon,  a position  he has held since the  Company's  inception  in
1998.

Dr. Longbin Liu, Dragon's  co-founding  President and CEO, has stepped down from
his management role and has been appointed  Chairman of the Board. He will focus
his efforts on providing strategic direction as well as scientific and technical
guidance to the Company.  Dr. Liu succeeds Dr. Ken Cai, co-founder of Dragon, as
Chairman.  Dr. Cai remains a Director of the Company and has been  appointed  to
the newly formed  Executive  Committee of the Board along with fellow  Directors
Dr. Wick and Mr. Philip Yuen.

"I am  delighted  that Alex has agreed to lead Dragon  through the next phase of
the Company's  development," said Dr. Liu. "With his extensive global experience
in the pharmaceutical  industry, I am confident that under his leadership Dragon
will  achieve  its full  potential  and I look  forward to  working  with him to
achieve this goal."

Dr. Wick's  extensive  career in the  pharmaceutical  industry  includes  senior
management  positions  in Europe and the U.S. Dr. Wick most  recently  served as
Chairman,  President and CEO of Sylachim S.A., an  international  fine chemicals
and manufacturer serving primarily the pharmaceutical industry, where he led all
aspects of the organization  including the strategic initiative resulting in the
company's  acquisition by the German  conglomerate  Dynamit-Nobel  GmbH in 2001.
Prior to Sylachim,  Dr. Wick's positions with notable  pharmaceutical  companies
include  12  years  in  research  with  Hoffmann-La  Roche  in  both  the US and
Switzerland and 15 years as  Vice-President  of Medicinal  Chemical Research and
Development  at  Synthelabo  S.A. in France.  Dr. Wick  continues  to serve as a
Director of a number of global pharmaceutical companies.

Dr. Wick is an organic chemist with a PhD degree in synthetic  organic chemistry
from the Swiss  Institute of  Technology  (Zurich) and  completed  post-doctoral
studies at Harvard University (Cambridge, Massachusetts).

"I am honored to have the opportunity to be President of Dragon," said Dr. Wick.
"On  behalf of  Dragon's  Board of  Directors,  I wish to  express  our  sincere
appreciation  to both Dr. Liu and Dr.  Cai for their  leadership  in  building a
strong  foundation  and  positioning  Dragon to become a major  supplier of high
quality therapeutic proteins. I am very much looking forward to working with the
Board and management team towards the Company's future success."


About Dragon Pharmaceuticals
Dragon    Pharmaceuticals   Inc.   is   a   fully   integrated,    international
biopharmaceutical   corporation  engaged  in  the  discovery,   development  and
commercialization of genetically  engineered human proteins for therapeutic use.
Based on its proprietary protein expression technology,  Dragon believes that it
has become one of the world's lowest cost producers of Erythropoietin  (EPO) - a
breakthrough  drug that has  revolutionized  the treatment of severe anemia with
estimated  worldwide sales of US$6 billion in 2001.  Dragon is also applying its
platform technology to the development of other branded as well as novel protein
drugs.

Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private
Securities Litigation Reform Act of 1995: All statements,  other than historical
facts,  included in the foregoing press release are forward-looking  statements.
These  statements  are based on  management's  beliefs and  assumptions,  and on
information  currently available to management.  Forward-looking  statements are
not  guarantees  of future  performance.  They involve risk,  uncertainties  and
assumptions  including  risks  discussed  under  "Risks  Associated  With Dragon
Pharmaceuticals"  in the  Company's  annual  report on Form 10-K,  SEC File No.:
0-27937, all of which are incorporated herein by reference. The Company does not
undertake the obligation to publicly revise these forward-looking  statements to
reflect subsequent events or circumstances.

For further information, please contact Carey Nelson, Manager Investor Relations
at  Tel:  (604)  669-8817  or Fax:  (604)  669-4243  or  visit  our web  site at
www.dragonbiotech.com  (http://www.dragonbiotech.com)
[{"type": "8-K", "sequence": "1", "filename": "for101002.txt", "description": "FOR 10/10/02", "secsgml_size_bytes": 6816}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICALS INC", "cik": "0001075206", "assigned-sic": "2834", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "02786153"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO"}}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) October 10, 2002

                           Dragon Pharmaceutical, Inc.
             (Exact name of registrant as specified in its charter)

            Florida                      0-27937                 65-0142474
            -------                      -------                 ----------
  (State or other jurisdiction of      (Commission            (I.R.S. Employer
  incorporation or organization)       File Number)          Identification No.)

                      1055 West Hastings Street, Suite 1900
                           Vancouver, British Columbia
                                 Canada V6E 2E9
                    (Address of principal executive offices)

                                 (604) 669-8817
                           (Issuer's telephone number)
Item 5.  Other Events and Regulation FD Disclosure

On October 10, 2002,  Dragon  Pharmaceutical  announced  that Alexander Wick had
been named as President and Chief Executive Officer.

A copy of the  press  release  announcing  the  naming of Mr.  Wick is  included
herewith as an exhibit to this report.

Item 7.  Financial Statements and Exhibits.

         (c)      Exhibits.

                  99.1     Press release dated October 10, 2002.

                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: October 10, 2002                     Dragon Pharmaceutical, Inc.
                                            a Florida Corporation

                                            /S/ Matthew Kavanagh
                                            ----------------------------
                                            Matthew Kavanagh,
                                            Principal Accounting Officer
Exhibit 99.1 Press Release

DRAGON APPOINTS NEW PRESIDENT

Vancouver,   BC  -  October  10,  2002  -  The  Board  of  Directors  of  Dragon
Pharmaceuticals Inc. (TSX: DDD; OTC BB: DRUG) today announced the appointment of
Dr.  Alexander  E.  Wick as  President.  Dr.  Wick will  continue  to serve as a
Director of Dragon,  a position  he has held since the  Company's  inception  in
1998.

Dr. Longbin Liu, Dragon's  co-founding  President and CEO, has stepped down from
his management role and has been appointed  Chairman of the Board. He will focus
his efforts on providing strategic direction as well as scientific and technical
guidance to the Company.  Dr. Liu succeeds Dr. Ken Cai, co-founder of Dragon, as
Chairman.  Dr. Cai remains a Director of the Company and has been  appointed  to
the newly formed  Executive  Committee of the Board along with fellow  Directors
Dr. Wick and Mr. Philip Yuen.

"I am  delighted  that Alex has agreed to lead Dragon  through the next phase of
the Company's  development," said Dr. Liu. "With his extensive global experience
in the pharmaceutical  industry, I am confident that under his leadership Dragon
will  achieve  its full  potential  and I look  forward to  working  with him to
achieve this goal."

Dr. Wick's  extensive  career in the  pharmaceutical  industry  includes  senior
management  positions  in Europe and the U.S. Dr. Wick most  recently  served as
Chairman,  President and CEO of Sylachim S.A., an  international  fine chemicals
and manufacturer serving primarily the pharmaceutical industry, where he led all
aspects of the organization  including the strategic initiative resulting in the
company's  acquisition by the German  conglomerate  Dynamit-Nobel  GmbH in 2001.
Prior to Sylachim,  Dr. Wick's positions with notable  pharmaceutical  companies
include  12  years  in  research  with  Hoffmann-La  Roche  in  both  the US and
Switzerland and 15 years as  Vice-President  of Medicinal  Chemical Research and
Development  at  Synthelabo  S.A. in France.  Dr. Wick  continues  to serve as a
Director of a number of global pharmaceutical companies.

Dr. Wick is an organic chemist with a PhD degree in synthetic  organic chemistry
from the Swiss  Institute of  Technology  (Zurich) and  completed  post-doctoral
studies at Harvard University (Cambridge, Massachusetts).

"I am honored to have the opportunity to be President of Dragon," said Dr. Wick.
"On  behalf of  Dragon's  Board of  Directors,  I wish to  express  our  sincere
appreciation  to both Dr. Liu and Dr.  Cai for their  leadership  in  building a
strong  foundation  and  positioning  Dragon to become a major  supplier of high
quality therapeutic proteins. I am very much looking forward to working with the
Board and management team towards the Company's future success."

About Dragon Pharmaceuticals
Dragon    Pharmaceuticals   Inc.   is   a   fully   integrated,    international
biopharmaceutical   corporation  engaged  in  the  discovery,   development  and
commercialization of genetically  engineered human proteins for therapeutic use.
Based on its proprietary protein expression technology,  Dragon believes that it
has become one of the world's lowest cost producers of Erythropoietin  (EPO) - a
breakthrough  drug that has  revolutionized  the treatment of severe anemia with
estimated  worldwide sales of US$6 billion in 2001.  Dragon is also applying its
platform technology to the development of other branded as well as novel protein
drugs.

Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private
Securities Litigation Reform Act of 1995: All statements,  other than historical
facts,  included in the foregoing press release are forward-looking  statements.
These  statements  are based on  management's  beliefs and  assumptions,  and on
information  currently available to management.  Forward-looking  statements are
not  guarantees  of future  performance.  They involve risk,  uncertainties  and
assumptions  including  risks  discussed  under  "Risks  Associated  With Dragon
Pharmaceuticals"  in the  Company's  annual  report on Form 10-K,  SEC File No.:
0-27937, all of which are incorporated herein by reference. The Company does not
undertake the obligation to publicly revise these forward-looking  statements to
reflect subsequent events or circumstances.

For further information, please contact Carey Nelson, Manager Investor Relations
at  Tel:  (604)  669-8817  or Fax:  (604)  669-4243  or  visit  our web  site at
www.dragonbiotech.com  (http://www.dragonbiotech.com)